{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:17:27Z","timestamp":1787771847783,"version":"build-2784847793"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010]]},"abstract":"\n Background:<\/jats:title>\n There is need to investigate the use of liposomal amphotericin B in cryptococcal meningitis in India.<\/jats:p>\n <\/jats:sec>\n \n Aims:<\/jats:title>\n \n To compare the efficacy, safety, duration of treatment and cost of two doses of liposomal amphotericin B (Amp B) (Fungisome\n TM<\/jats:sup>\n ) in cryptococcal meningitis in HIV\/AIDS patients.\n <\/jats:p>\n <\/jats:sec>\n \n Settings and Design:<\/jats:title>\n Prospective, randomized, multicenter study in tertiary care hospitals across India.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n Adult patients with culture-proven cryptococcal meningitis with HIV\/AIDS were randomized to receive either 1 (Group A) or 3 mg\/kg\/day of Fungisome (Group B). Clinical efficacy and tolerability, laboratory evaluations and mycological response were assessed daily, twice weekly and weekly respectively. The patients were assessed at four and eight-week follow-up.<\/jats:p>\n <\/jats:sec>\n \n Statistics:<\/jats:title>\n We calculated average and standard deviation for the various parameters.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n The time to show clinical response was 13.66 days (1 mg) and 9.55 days (3 mg). In Group B (n=6 complete response), 50% patients responded within one week by microbial conversion, 83% in two weeks and 100% in three weeks. Patients with 1 mg dose (n=4 complete response), none showed microbial conversion within one week, 75% responded in two weeks, whereas one patient took four weeks. The average duration of treatment was 36.5\u00b114.4 and 26.5\u00b15.89 (S.D.) days in 1 and 3 mg\/kg\/day respectively. Drug was tolerated with little renal, hepatic or hematological toxicity. The cost was found to be 3.81 lacs and 1.74 lacs with 3mg\/kg\/day and 1mg\/kg\/day respectively.<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Higher dose showed better efficacy and quicker microbial conversion of Cerebrospinal fluid (CSF) (cerebrospinal fluid) than 1 mg\/kg\/day. It shortened the duration of treatment in days by 27% while drug cost almost doubled (Clinical trial registration number: ISRTCN 52812742)<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/0022-3859.65276","type":"journal-article","created":{"date-parts":[[2010,7,8]],"date-time":"2010-07-08T07:28:15Z","timestamp":1278574095000},"page":"71-75","source":"Crossref","is-referenced-by-count":20,"title":["Liposomal amphotericin B (FungisomeTM) for the treatment of cryptococcal meningitis in HIV\/AIDS patients in India"],"prefix":"10.4103","volume":"56","author":[{"given":"MP","family":"Jadhav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Bamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VM","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Gogtay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NA","family":"Kshirsagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LS","family":"Bichile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Mathai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Digumarathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20240205","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/infdis\/157.4.624","article-title":"Cryptococcal meningitis in patients with AIDS","volume":"157","author":"Dismukes","year":"1988","journal-title":"J Infect Dis"},{"key":"R2-4-20240205","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJM198909213211205","article-title":"Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome","volume":"321","author":"Chuck","year":"1989","journal-title":"N Engl J Med"},{"key":"R3-4-20240205","doi-asserted-by":"crossref","first-page":"234","DOI":"10.7326\/0003-4819-104-2-234","article-title":"Cryptococcal disease in patients with acquired immunodeficiency syndrome: Diagnostic features and outcome of treatment","volume":"104","author":"Zuger","year":"1986","journal-title":"Ann Intern Med"},{"key":"R4-4-20240205","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1056\/NEJM199201093260202","article-title":"Comparison of Amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis","volume":"326","author":"Saag","year":"1992","journal-title":"N Engl J Med"},{"key":"R5-4-20240205","doi-asserted-by":"crossref","first-page":"183","DOI":"10.7326\/0003-4819-113-3-183","article-title":"Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS","volume":"113","author":"Larsen","year":"1990","journal-title":"Ann Intern Med"},{"key":"R6-4-20240205","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00002030-199202000-00007","article-title":"Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis","volume":"6","author":"Gans","year":"1992","journal-title":"AIDS"},{"key":"R7-4-20240205","first-page":"S5","article-title":"Liposomal drug delivery system from laboratory to clinic","volume":"51","author":"Kshirsagar","year":"2005","journal-title":"J Postgrad Med"},{"key":"R8-4-20240205","first-page":"75","article-title":"Preclinical and pharmaceutical testing of liposomal amphotericin B","volume":"98","author":"Gokhale","year":"1993","journal-title":"Indian J Med Res Br"},{"key":"R9-4-20240205","first-page":"448","article-title":"Development and therapeutic of liposomal amphotericin B","volume":"65","author":"Gokhale","year":"1993","journal-title":"Curr Sci"},{"key":"R10-4-20240205","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/jac\/32.1.133","article-title":"Pharmacokinetics and tolerance of amphotericin B in patients","volume":"32","author":"Gokhale","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"R11-4-20240205","first-page":"333","article-title":"Liposomal drug delivery system form laboratory to patients: Our experience","volume":"68","author":"Kshirsagar","year":"2002","journal-title":"Proc Indian Natl Sci Acad"},{"key":"R12-4-20240205","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-113-3-177","article-title":"Fluconaozle a new antifungal agent","volume":"113","author":"Galgiani","year":"1990","journal-title":"Ann Intern Med"},{"key":"R13-4-20240205","first-page":"S21","article-title":"Clinical manifestation and management of cryptococcal infections","volume":"51","author":"Subramanian","year":"2005","journal-title":"J Postgrad Med"},{"key":"R14-4-20240205","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0002-9343(68)90075-2","article-title":"Treatment of disseminated mycotic infection: A new approach to amphotericin B therapy","volume":"45","author":"Drutz","year":"1968","journal-title":"Am J Med"},{"key":"R15-4-20240205","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/00002030-199712000-00010","article-title":"Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis","volume":"11","author":"Leenders","year":"1997","journal-title":"AIDS"},{"key":"R16-4-20240205","first-page":"1086","article-title":"Safety and efficacy of liposomal amphotericin B in patients with cryptococcal meningitis","volume":"49","author":"Kotwani","year":"2001","journal-title":"J Assoc Physics India"},{"key":"R17-4-20240205","first-page":"465","article-title":"Successful treatment of cryptococcal meningitis with a combination of liposomal amphotericin B, flucytosine and posaconazole: two case reports","volume":"23","author":"Esposito","year":"2009","journal-title":"In Vivo"},{"key":"R18-4-20240205","first-page":"CD005647","article-title":"Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings","volume":"8","author":"Sloan","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"R19-4-20240205","first-page":"662","article-title":"Open lable, randomized, comparative phase III safety and efficacy study with conventional amphotericin B and liposomal amphotericin B in patients with systemic fungal infections","volume":"50","author":"Bodhe","year":"2002","journal-title":"J Assoc Physics India"}],"container-title":["Journal of Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005257-201056020-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:17:33Z","timestamp":1787768253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005257-201056020-00004"}},"subtitle":["A multicentric, randomized controlled trial"],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.4103\/0022-3859.65276","relation":{},"ISSN":["0022-3859"],"issn-type":[{"value":"0022-3859","type":"print"}],"subject":[],"published":{"date-parts":[[2010]]}}}